SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th

Rhea-AI Summary

SELLAS Life Sciences Group (NASDAQ: SLS), a biopharmaceutical firm, will present at the JMP Securities Life Sciences Conference on June 15, 2022, at 11:00 a.m. ET. CEO Angelos Stergiou will lead the presentation at the Lotte New York Palace.

SELLAS focuses on developing novel cancer therapies. Its lead candidate, GPS, targets the WT1 protein in various tumors and could be used alone or with other treatments. Additionally, the company is developing GFH009, a selective CDK9 inhibitor licensed from GenFleet Therapeutics.

NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS, will present at the JMP Securities Life Sciences Conference to be held at the Lotte New York Palace in New York City on Wednesday, June 15, 2022, at 11:00 a.m. ET.

For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your JMP Securities representative directly, or send an email to KCSA Strategic Communications at SELLAS@kcsa.com.

About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Investor Contact
Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com  
Phone: 212.896.1267

Media Contact
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
Email: SELLAS@kcsa.com  
Phone: 212.896.1204

FAQ

What is SELLAS Life Sciences Group's focus?

SELLAS focuses on developing novel therapies for a wide range of cancer indications.

When will SELLAS present at the JMP Securities Life Sciences Conference?

SELLAS will present on June 15, 2022, at 11:00 a.m. ET.

Who is presenting for SELLAS at the conference?

Angelos Stergiou, the President and CEO of SELLAS, will present.

What is the lead product candidate of SELLAS?

The lead product candidate is GPS, which targets the WT1 protein in various tumor types.

What is GFH009 developed by SELLAS?

GFH009 is a highly selective CDK9 inhibitor licensed from GenFleet Therapeutics for global use outside Greater China.